Idexx Laboratories Inc. (IDXX) Shares Bought by Headinvest LLC
Headinvest LLC boosted its stake in shares of Idexx Laboratories Inc. (NASDAQ:IDXX) by 8.0% during the second quarter, Holdings Channel reports. The fund owned 67,751 shares of the company’s stock after buying an additional 5,000 shares during the period. Idexx Laboratories comprises approximately 2.4% of Headinvest LLC’s investment portfolio, making the stock its 8th largest position. Headinvest LLC’s holdings in Idexx Laboratories were worth $6,291,000 at the end of the most recent quarter.
Several other institutional investors have also recently added to or reduced their stakes in IDXX. Fundsmith LLP boosted its position in shares of Idexx Laboratories by 69.0% in the first quarter. Fundsmith LLP now owns 4,210,679 shares of the company’s stock worth $329,780,000 after buying an additional 1,719,511 shares in the last quarter. Norges Bank bought a new position in shares of Idexx Laboratories during the fourth quarter worth approximately $59,478,000. Renaissance Technologies LLC boosted its position in shares of Idexx Laboratories by 242.6% in the first quarter. Renaissance Technologies LLC now owns 437,504 shares of the company’s stock worth $34,265,000 after buying an additional 309,804 shares in the last quarter. Old Mutual Global Investors UK Ltd. boosted its position in shares of Idexx Laboratories by 270.4% in the second quarter. Old Mutual Global Investors UK Ltd. now owns 270,088 shares of the company’s stock worth $25,080,000 after buying an additional 197,177 shares in the last quarter. Finally, Smith Asset Management Group LP bought a new position in shares of Idexx Laboratories during the second quarter worth approximately $12,467,000. 91.58% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Idexx Laboratories Inc. (NASDAQ:IDXX) traded up 0.91% on Thursday, hitting $113.09. The stock had a trading volume of 442,241 shares. Idexx Laboratories Inc. has a 12 month low of $63.48 and a 12 month high of $115.06. The firm has a market cap of $10.13 billion, a P/E ratio of 51.26 and a beta of 0.56. The firm’s 50-day moving average price is $111.08 and its 200 day moving average price is $92.50.
Idexx Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, August 2nd. The company reported $0.74 earnings per share for the quarter, topping analysts’ consensus estimates of $0.62 by $0.12. The business earned $467 million during the quarter, compared to the consensus estimate of $444.83 million. Idexx Laboratories had a net margin of 11.94% and a negative return on equity of 414.67%. The company’s revenue was up 12.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.60 earnings per share. Analysts anticipate that Idexx Laboratories Inc. will post $2.36 EPS for the current fiscal year.
A number of equities analysts recently commented on the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $120.00 target price on shares of Idexx Laboratories in a report on Monday, August 22nd. Stifel Nicolaus increased their price target on Idexx Laboratories from $120.00 to $125.00 and gave the stock a “buy” rating in a research note on Tuesday, August 16th. Zacks Investment Research upgraded Idexx Laboratories from a “hold” rating to a “buy” rating and set a $121.00 price target for the company in a research note on Thursday, August 4th. Finally, Northcoast Research upgraded Idexx Laboratories from a “sell” rating to a “neutral” rating in a research note on Wednesday, August 3rd. Three equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The stock currently has an average rating of “Buy” and an average target price of $105.20.
In related news, Director Rebecca M. Henderson sold 9,924 shares of the company’s stock in a transaction dated Thursday, August 25th. The shares were sold at an average price of $110.43, for a total transaction of $1,095,907.32. Following the completion of the sale, the director now owns 16,678 shares of the company’s stock, valued at approximately $1,841,751.54. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, Director William T. End sold 5,000 shares of the company’s stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $108.50, for a total transaction of $542,500.00. Following the sale, the director now directly owns 53,564 shares of the company’s stock, valued at approximately $5,811,694. The disclosure for this sale can be found here. Corporate insiders own 2.79% of the company’s stock.
About Idexx Laboratories
Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Idexx Laboratories Inc. (NASDAQ:IDXX).
Receive News & Ratings for Idexx Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idexx Laboratories Inc. and related companies with MarketBeat.com's FREE daily email newsletter.